Professor Adrienne M Flanagan received her medical degree from the Royal College of Surgeons in Ireland and undertook her PhD at the University of London in 1990 while she was a Medical Research Council Training Fellow at St. George’s Hospital Medical School in London. She became a senior lecturer and honorary consultant pathologist at Imperial College London, later moved to University College London, and now practices clinical pathology at the Royal National Orthopaedic Hospital. She was elected as professor of musculoskeletal pathology at UCL’s Cancer Institute in 2004. She is the meeting secretary of the Pathological Society of Great Britain and Ireland and a trustee or member of the Sarcoma UK, the Jean Shanks Foundation, and the Chordoma Foundation (USA). Her research interests focus on reclassifying bone and soft tissue tumours using molecular signatures, which she then translates into clinical practice and uses for stratifying patients for treatment. She was the co-lead of the International Cancer Genome Consortium bone tumour project (2010–2015). In 2017, she became a senior NIHR Fellow and was awarded the Goudie for her contribution to pathological science and the understanding of disease mechanisms. She was also awarded the William Gerald Award by the Department of Pathology Memorial Sloan Kettering Cancer Centre in recognition for her contribution to research in cancer pathology.
Professor Sandra J Strauss is a senior clinical lecturer and honorary consultant medical oncologist. Her clinical post is based at University College London Hospital, part of the London Sarcoma Service, one of the largest sarcoma services in Europe. She specialises in the systemic treatment of bone and soft tissue sarcomas in both adults and teenagers. She completed a Cancer Research UK Clinical Fellowship to obtain a PhD (University of London) at St. Bartholomew’s Hospital. In 2009, she was awarded a Career Development Award from the Sarcoma Alliance for Research through Collaboration (SARC). Her research interest is in identifying new targets for therapy in osteosarcoma and Ewing’s sarcoma and developing early-phase clinical trials. She is the chief investigator and principal investigator for a number of international and national phase I, II, and III studies in sarcoma and is leading a national cohort study in osteosarcoma, ICONIC. She was appointed chair of the Executive Committee of the European EuroEwing consortium (EEC). She is also a member of the EORTC Soft Tissue and Bone Sarcoma Group and Innovative Therapies for Children with Cancer (ITCC) consortium and is the clinical lead for sarcoma and rare cancers for the Public Health England (PHE) National Cancer Registration and Analysis Service (NCRAS).
